254 related articles for article (PubMed ID: 3922373)
1. Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid.
Patscheke H
Biochem Pharmacol; 1985 Apr; 34(8):1151-6. PubMed ID: 3922373
[TBL] [Abstract][Full Text] [Related]
2. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
3. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate.
Hornberger W; Patscheke H
Eicosanoids; 1989; 2(4):241-8. PubMed ID: 2517034
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
5. Hydrogen peroxide and methyl mercury are primary stimuli of eicosanoid release in human platelets.
Hornberger W; Patscheke H
J Clin Chem Clin Biochem; 1989 Sep; 27(9):567-75. PubMed ID: 2481709
[TBL] [Abstract][Full Text] [Related]
6. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
Parry MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
[TBL] [Abstract][Full Text] [Related]
7. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.
Gresele P; Deckmyn H; Huybrechts E; Vermylen J
Biochem Pharmacol; 1984 Jul; 33(13):2083-8. PubMed ID: 6430299
[TBL] [Abstract][Full Text] [Related]
8. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
Bertele V; De Gaetano G
Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
[TBL] [Abstract][Full Text] [Related]
9. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
de Chaffoy de Courcelles D; De Clerck F
Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
11. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
[TBL] [Abstract][Full Text] [Related]
13. Platelet desensitization induced by arachidonic acid is not due to cyclo-oxygenase inactivation and involves the endoperoxide receptor.
Carmo LG; Hatmi M; Rotilio D; Vargaftig BB
Br J Pharmacol; 1985 Aug; 85(4):849-59. PubMed ID: 2994786
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G
Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554
[TBL] [Abstract][Full Text] [Related]
15. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production.
Cattaneo M; Tenconi PM; Lecchi A; Mannucci PM
Thromb Res; 1991 Jun; 62(6):717-24. PubMed ID: 1926062
[TBL] [Abstract][Full Text] [Related]
16. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism.
Patrignani P; Filabozzi P; Catella F; Pugliese F; Patrono C
J Pharmacol Exp Ther; 1984 Feb; 228(2):472-7. PubMed ID: 6537977
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of thromboxane and 12-HPETE formation by dazoxiben and its two thiophenic acid-substituted derivatives.
Smith EF; Darius H; Ferber H; Schrör K
Eur J Pharmacol; 1985 Jun; 112(2):161-9. PubMed ID: 3896821
[TBL] [Abstract][Full Text] [Related]
20. Thromboxane-mediated activation of platelets and enhancement of platelet uptake onto collagen-coated glass or deendothelialized rabbit aorta. Comparative effects of a thromboxane antagonist (EPO45) and a thromboxane synthetase inhibitor (dazoxiben).
Menys VC; Davies JA
Lab Invest; 1984 Feb; 50(2):184-9. PubMed ID: 6546403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
